Advertisement

Breast Cancer Research and Treatment

, Volume 123, Issue 3, pp 877–883 | Cite as

NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis

  • Jian Zhang
  • Li-Xin Qiu
  • Zhong-Hua Wang
  • Jia-Lei Wang
  • Shuang-Shuang He
  • Xi-Chun Hu
Epidemiology

Abstract

To derive a more precise estimation of the relationship between the slow or rapid acetylation resulting from N-acetyltransferase 2 (NAT2) polymorphisms and breast cancer risk, a meta-analysis was performed. PubMed, Medline, Embase, and Web of Science were searched. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess strength of association. The pooled ORs were performed for slow versus rapid acetylation genotypes. A total of 26 studies including 9,215 cases and 10,443 controls were included in the meta-analysis. Overall, no significantly elevated breast cancer risk was associated with NAT2 slow genotypes when all studies were pooled into the meta-analysis (OR = 1.026, 95% CI = 0.968–1.087). In the subgroup analysis by ethnicity, increased risks were not found for either Caucasians (OR = 1.001, 95% CI = 0.938–1.068) or Asians (OR = 1.155, 95% CI = 0.886–1.506). When stratified by study design, statistically significantly elevated risk associated with NAT2 slow genotypes was only found among hospital-based studies (OR = 1.178, 95% CI = 1.037–1.339). In the subgroup analysis by menopausal status, no statistically significantly increased risk was found in either premenopausal (OR = 1.053, 95% CI = 0.886–1.252) or postmenopausal women (OR = 0.965, 95% CI = 0.844–1.104). When stratified by cumulative smoking exposure, in the subgroup of smokers with high pack-years, NAT2 slow genotypes were significantly associated with increased breast cancer risk (OR = 1.400, 95% CI = 1.099–1.784). In conclusion, this meta-analysis suggested that there is overall lack of association between NAT2 genotypes and breast cancer risk, however, NAT2 polymorphisms when combining with heavy smoking history may contribute to breast cancer susceptibility.

Keywords

NAT2 Polymorphism Breast cancer Smoking Susceptibility Meta-analysis 

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMedGoogle Scholar
  2. 2.
    Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med 9:208–221CrossRefPubMedGoogle Scholar
  3. 3.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85CrossRefPubMedGoogle Scholar
  4. 4.
    Smith CA, Smith G, Wolf CR (1994) Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A:1921–1935CrossRefPubMedGoogle Scholar
  5. 5.
    Hein DW (1988) Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948:37–66PubMedGoogle Scholar
  6. 6.
    Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506–507:65–77PubMedGoogle Scholar
  7. 7.
  8. 8.
    Agundez JA, Ladero JM, Olivera M, Abildua R, Roman JM, Benitez J (1995) Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 52:7–11CrossRefPubMedGoogle Scholar
  9. 9.
    Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, Shields PG (1996) Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276:1494–1501CrossRefPubMedGoogle Scholar
  10. 10.
    Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, Manson JE, Colditz GA, Willett WC, Speizer FE, Kelsey K (1997) A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 18:2127–2132CrossRefPubMedGoogle Scholar
  11. 11.
    Millikan RC, Pittman GS, Newman B, Tse CK, Selmin O, Rockhill B, Savitz D, Moorman PG, Bell DA (1998) Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:371–378PubMedGoogle Scholar
  12. 12.
    Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ (1999) Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int J Cancer 82:175–179CrossRefPubMedGoogle Scholar
  13. 13.
    Morabia A, Bernstein MS, Bouchardy I, Kurtz J, Morris MA (2000) Breast cancer and active and passive smoking: the role of the N-acetyltransferase 2 genotype. Am J Epidemiol 152:226–232CrossRefPubMedGoogle Scholar
  14. 14.
    Delfino RJ, Smith C, West JG, Lin HJ, White E, Liao SY, Gim JS, Ma HL, Butler J, Anton-Culver H (2000) Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 10:461–469CrossRefPubMedGoogle Scholar
  15. 15.
    Deitz AC, Zheng W, Leff MA, Gross M, Wen WQ, Doll MA, Xiao GH, Folsom AR, Hein DW (2000) N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 9:905–910PubMedGoogle Scholar
  16. 16.
    Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D (2001) Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 92:220–225CrossRefPubMedGoogle Scholar
  17. 17.
    Wu FY, Lee YJ, Chen DR, Kuo HW (2002) Association of DNA-protein crosslinks and breast cancer. Mutat Res 501:69–78PubMedGoogle Scholar
  18. 18.
    Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A (2002) Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:698–704PubMedGoogle Scholar
  19. 19.
    Matheson MC, Stevenson T, Akbarzadeh S, Propert DN (2002) GSTT1 null genotype increases risk of premenopausal breast cancer. Cancer Lett 181:73–79CrossRefPubMedGoogle Scholar
  20. 20.
    Egan KM, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Mignone LI, Farin F, Hunter DJ (2003) Association of NAT2 and smoking in relation to breast cancer incidence in a population-based case–control study (United States). Cancer Causes Control 14:43–51CrossRefPubMedGoogle Scholar
  21. 21.
    Lee KM, Park SK, Kim SU, Doll MA, Yoo KY, Ahn SH, Noh DY, Hirvonen A, Hein DW, Kang D (2003) N-Acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Lett 196:179–186CrossRefPubMedGoogle Scholar
  22. 22.
    van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, Bueno DMH (2003) NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13:399–407CrossRefPubMedGoogle Scholar
  23. 23.
    Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE (2004) N-Acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case–control study of Turkish population. Int J Toxicol 23:25–31CrossRefPubMedGoogle Scholar
  24. 24.
    Alberg AJ, Daudt A, Huang HY, Hoffman SC, Comstock GW, Helzlsouer KJ, Strickland PT, Bell DA (2004) N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect Prev 28:187–193CrossRefPubMedGoogle Scholar
  25. 25.
    Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K (2005) NAT2 slow acetylator genotype as an important modifier of breast cancer risk. Int J Cancer 114:579–584CrossRefPubMedGoogle Scholar
  26. 26.
    Lilla C, Risch A, Kropp S, Chang-Claude J (2005) SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case–control study. Breast Cancer Res 7:R229–R237CrossRefPubMedGoogle Scholar
  27. 27.
    Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, Sherman ME, Szeszenia-Dabrowska N, Chanock S, Garcia-Closas M (2006) Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer 119:1961–1969CrossRefPubMedGoogle Scholar
  28. 28.
    Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W (2006) Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan. Breast 15:754–761CrossRefPubMedGoogle Scholar
  29. 29.
    Sillanpaa P, Heikinheimo L, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Metsola K, Hirvonen A (2007) CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population. Breast Cancer Res Treat 104:287–297CrossRefPubMedGoogle Scholar
  30. 30.
    Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed SB, Chouchane L (2008) Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8:109CrossRefPubMedGoogle Scholar
  31. 31.
    Egeberg R, Olsen A, Autrup H, Christensen J, Stripp C, Tetens I, Overvad K, Tjonneland A (2008) Meat consumption, N-acetyl transferase 1 and 2 polymorphism and risk of breast cancer in Danish postmenopausal women. Eur J Cancer Prev 17:39–47CrossRefPubMedGoogle Scholar
  32. 32.
    Baumgartner KB, Schlierf TJ, Yang D, Doll MA, Hein DW (2009) N-acetyltransferase 2 genotype modification of active cigarette smoking on breast cancer risk among hispanic and non-hispanic white women. Toxicol Sci 112:211–220CrossRefPubMedGoogle Scholar
  33. 33.
    Rabstein S, Bruning T, Harth V, Fischer HP, Haas S, Weiss T, Spickenheuer A, Pierl C, Justenhoven C, Illig T, Vollmert C, Baisch C, Ko YD, Hamann U, Brauch H, Pesch B (2010) N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer. Eur J Cancer Prev 19:100–109CrossRefPubMedGoogle Scholar
  34. 34.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedGoogle Scholar
  35. 35.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  36. 36.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  37. 37.
    Hoffmann D, Hoffmann I, El-Bayoumy K (2001) The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14:767–790CrossRefPubMedGoogle Scholar
  38. 38.
    Faraglia B, Chen SY, Gammon MD, Zhang Y, Teitelbaum SL, Neugut AI, Ahsan H, Garbowski GC, Hibshoosh H, Lin D, Kadlubar FF, Santella RM (2003) Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis 24:719–725CrossRefPubMedGoogle Scholar
  39. 39.
    Naito S, Tanaka K, Koga H, Kotoh S, Hirohata T, Kumazawa J (1995) Cancer occurrence among dyestuff workers exposed to aromatic amines. A long term follow-up study. Cancer 76:1445–1452CrossRefPubMedGoogle Scholar
  40. 40.
    Hoffmann D, Hoffmann I (1997) The changing cigarette, 1950–1995. J Toxicol Environ Health 50:307–364CrossRefPubMedGoogle Scholar
  41. 41.
    Talaska G (2003) Aromatic amines and human urinary bladder cancer: exposure sources and epidemiology. J Environ Sci Health C 21:29–43CrossRefGoogle Scholar
  42. 42.
    Swaminathan S, Frederickson SM, Hatcher JF (1994) Metabolic activation of N-hydroxy-4-acetylaminobiphenyl by cultured human breast epithelial cell line MCF 10A. Carcinogenesis 15:611–617CrossRefPubMedGoogle Scholar
  43. 43.
    Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, Et A (1994) Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:154–156CrossRefPubMedGoogle Scholar
  44. 44.
    Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D (2002) Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23:301–306CrossRefPubMedGoogle Scholar
  45. 45.
    Michnovicz JJ, Naganuma H, Hershcopf RJ, Bradlow HL, Fishman J (1988) Increased urinary catechol estrogen excretion in female smokers. Steroids 52:69–83CrossRefPubMedGoogle Scholar
  46. 46.
    Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis P (1993) Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 29A:1199–1207CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Jian Zhang
    • 1
    • 2
  • Li-Xin Qiu
    • 1
    • 2
  • Zhong-Hua Wang
    • 1
    • 2
  • Jia-Lei Wang
    • 1
    • 2
  • Shuang-Shuang He
    • 3
  • Xi-Chun Hu
    • 1
    • 2
  1. 1.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Shanghai Jiaotong University Affiliated First People’s HospitalShanghaiChina

Personalised recommendations